Recent advances in the nonsurgical treatment of upper gastrointestinal tract tumors

References

• Therasse P, Arbuck SG, Eisenhauer EA et al New guidelines to evaluate the response to treatment in solid turnouts. j Natl Cancer Inst. 92, 205–216 (2000).
   PubMed Web of Science ®Google Scholar
• •Important new response criteria (RECIST).
   Google Scholar
• Devessa SS, Blot WJ, Fraumeni JE Changing patterns in the incidence of oesophageal and gastric carcinoma in the United States. Cancer 83, 2049–2053 (1998).
   PubMedGoogle Scholar
• Wobst A, Audisio RA, Colleoni M, Geraghty JG. Oesophageal cancer treatment: studies, strategies and facts. Ann. Oncol 9, 951–962 (1998).
   PubMed Web of Science ®Google Scholar
• Clark PI. Medical Research Council randomised trial of surgery with or without preoperative chemotherapy in resectable cancer of the oesophagus. (MRC Upper GI Tract Cancer Group). Ann. Oncolll, 4, 20 (2000).
   Google Scholar
• •Important study establishing the role of neoadjuvant chemotherapy in esophageal cancer.
   Google Scholar
• Kok TC, van Lanshot J, Siersema PD, van Overhagen H, Tilanus HW. Neoadjuvant chemotherapy in operable esophageal squamous cell cancer: final report of a Phase III multicenter randomized controlled trial. Proc. Am Soc. Clin. Oncol 16, 277a (1997).
   Google Scholar
• Herskovic A, Martz K, Al—Sarraf M et al Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the oesophagus. N Engl. I Med. 326, 1593–1598 (1992).
   PubMed Web of Science ®Google Scholar
• ••Pivotal study establishing the role ofchemoradiation in the management of esophageal carcinomas.
   Google Scholar
• Cooper JS, Guo MD, Herskovic A et al Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85–01). jAm. Med. Assoc 281, 1623–1627 (1999).
   Google Scholar
• Walsh TN, Noonan N, Holywood D. A comparison of multimodal therapy and surgery for oesophageal adenocarcinoma. N. Engl. Med 335, 462–7 (1996).
   Google Scholar
• Urba SG, Orringer MB, Turrisi A eta]. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.j Clin. Oncol 19, 305–313 (2001).
   Google Scholar
• Boyce HW. Palliation of dysphagia of esophageal cancer by endoscopic luman restoration techniques. Cancer Control: Moffitt Cancer Center6, 73–83 (1999).
   PubMedGoogle Scholar
• Adelstein DJ, Rice TW, Rybicki L et al. Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy. J. Clin. Oncol 18, 2032–2039 (2000).
   PubMed Web of Science ®Google Scholar
• Minsky BD, Berkey B, Kasen D. Preliminary results of Intergroup TNT 0123 randomized trial of combined modality therapy (CMT) for esophageal cancer: Standard vs. high dose radiation therapy. Proc. Am. Soc. Clin. Oncol 19, 239a (2000).
   Google Scholar
• Choy H. Concomitant chemoradiotherapy. Oncology13, 11–168 (1999).
   PubMedGoogle Scholar
• Roukos DH. Current status and future perspectives in gastric cancer. Cancer Treat. Rev 26, 243–255 (2000).
   PubMedGoogle Scholar
• Kang YK, Choi DW, Im Y-H eta]. A Phase III randomized comparison of neoadjuvant chemotherapy followed by surgery versus surgery for locally advanced stomach cancer. Proc. Am. Soc. Clin. Oncol 15, 215 (1996).
   Google Scholar
• Yonemura Y, Sawa T, Kinoshita K. Neoadjuvant chemotherapy for high-grade advanced gastric cancer. Worldj Surg. 17, 256 (1993).
   Google Scholar
• Zhang ZX, Gu XZ, Yin WB. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of the gastric cardia — report on 370 patients. int. J. Racliat. OncolPhys 42, 929-934(1998).
   Google Scholar
• Hermans J, Bonenkamp JJ, Boon MC et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. 1 Clin. Oncolll, 1441–1447 (1993).
   Google Scholar
• •Important meta-analysis of adjuvant treatment in gastric cancer.
   Google Scholar
• Hallissey MT Dunn JA, Ward LC, Allum WH. The second British Stomach Cancer Group Trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: a five year follow-up. Lancet343, 1309–1312 (1994).
   PubMedGoogle Scholar
• Macdonald JS, Smalley S, Benedetti J et al. Postoperative combined radiotherapy and chemotherapy improves disease-free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and GE junction. Proc. Am. Soc. Clin. Oncol 19, la (2000).
   Google Scholar
• •Important study demonstrating a survival advantage for adjuvant chemoradiation in patients following resection for gastric cancer.
   Google Scholar
• Rosen HR, Jatzko G, Repse S et al. Adjuvant intraperitoneal chemotherapy with carbon-absorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology. J. Clin. Oncol 16(8), 2733–2738 (1998).
   Google Scholar
• Alexander HR, Kasen DG, Tepper JC. Cancer of the stomach. In: Cancer: Principles and Practice of Oncologx (Volume 2, Fifth Frlition). DeVita VT Hellman S, Rosenberg SA (Eds.), Lippincott-Raven Publishers, Philadelphia, USA, 1021–1054 (1997).
   Google Scholar
• Cullinan SA, Moertel CG, Fleming TR. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinomas. J. Am. Med. Assoc. 253, 2061–2067 (1985).
   Google Scholar
• Wils 0, Klein HO, Wagener DJT. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin : a step ahead in the treatment of gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract co-operative Group. J. Clin. Oncol 9, 827–831 (1991).
   Google Scholar
• Webb A, Cunningham D, Scarffe JH eta]. Randomized trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin and methotrexate in advanced esophagogastric cancer. j Clin. Oncol 15, 261–267 (1997).
   Google Scholar
• •Probably the best combination chemotherapy for advanced gastric cancer.
   Google Scholar
• Lack° A, Woll PJ, Langley RE, Thomas A, Carmichael J. CEF chemotherapy for advanced gastroesophageal cancer. Eur. Cancer33, 1272 (1997).
   Google Scholar
• Cascinu S, Labianca R, Alessandroni Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epidoxorubicin, 65-leucovorin, glutathione and filgrastim. j Clin. Oncol 15, 3313–3319 (1997).
   Google Scholar
• Vanhoefer U, Rougier P, Wilke H et al. Final results of a randomized Phase III trial of sequential high-dose methotrexate, fluorouracil and doxorubicin versus etoposide, leucovorin and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J. Clin. Oncol 18, 2648–2657 (2000).
   PubMed Web of Science ®Google Scholar
• Cookes P, Leichman CG, Leichman G. Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy. Cancer 79, 1767–1775 (1997).
   Google Scholar
• Tierney GM, Griffin NR, Stuart SC. A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer. Cancer 35, 563–568 (1999).
   Google Scholar
• Fielding J, Schofield J, Cutsern R, Thloracius-Ussing 0, Hovendal C. A randomized double-blind placebo-controlled study of marimastat in patients with inoperable gastric adenocarcinoma. Proc. Am. Assoc. Clin. Oncol 19, 240a (2000).
   Google Scholar
• Kalser MH, Ellenberg SS. Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Amh. Surg. 120, 899–903 (1985).
   Google Scholar
• Bakkevold KE, Arnesjo B, Dahl 0, Kambestad B. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater — results of a controlled, prospective, randomised multicentre study. Eur. J. Cancer 29A 5, 698–703 (1993).
   Google Scholar
• Klinkenbijl JH, Jeekel J, Sahmoud T Adjuvant radiotherapy and 5-fluorouracil after curative resection for the cancer of the pancreas and peri-ampullary region: Phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative. Ann. Surg. 230, 776–784 (1999).
   Google Scholar
• Yeo CJ, Abrams RA, Grochow LB et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. Ann. Sing. 225, 621–636 (1997).
   Google Scholar
• Neoptolemos JP, Dunn JA, Moffitt DD. ESPAC-1 interim results: a European randomised study to assess the role of adjuvant chemotherapy (5-FU + folinic
   Google Scholar
• •• acid) and adjuvant chemoradiation (40 Gy and 5-FU) in resectable pancreatic cancer. Pmc. A117. Soc. Gun. 017C01 19,238a (2000).
   Google Scholar
• Staley CA, Lee JE, Cleary KA. Preoperative chemoradiation, pancreaticoduodenectomy and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Ainj Surg. 171, 118–125 (1996).
   Google Scholar
• Pisters PW, Abbruzzese JL, Janjan NA. Rapid fractionation preoperative chemoradiation, pancreaticoduodenectomy and intraoperative radiation therapy for adenocarcinoma of the pancreas. j Clin. Oncol 16, 3843–3850 (1998).
   Google Scholar
• Moertel CG, Childs DS, Reitemeier RJ. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable cancer. Lancet 865–867 (1969).
   Google Scholar
• Moertel CG, Frytak S, Hahn RG. Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5FU) and high dose radiation + 5FU — the Gastrointestinal Tumour Study Group. Cancer 48, 1705–1710 (1981).
   Google Scholar
• KLaasen DJ, MacIntyre JM, Catton GE, Engstrom PF, Moertel CG. Treatment of locally unresectable cancer of the stomach and pancreas: an Eastern Cooperative Oncology Group study. j Clin. 0=1 3, 373–378 (1985).
   Google Scholar
• Rougier P, Ducreux M, Douillard JY. Efficacy of 5FU + cisplatin (PUP) compared to bolus 5FU (FU) in advanced Pancreatic carcinoma (AFC): A randomized trial from the French Anticancer Centers Digestive Group (FNLCCDG). Proc. Am. Soc. Clin. Oncol 18, 1050 (1999).
   Google Scholar
• Pazdur R, Meropol NJ, Casper ES et al. Phase II trial of ZD1694 (TOMUDEX) in patients with advanced pancreatic cancer. Invest. New Drugs 13, 355–358 (1996).
   Google Scholar
• Abbruzzese JL, Evans D, Markowitz A. Docetaxel, a potentially active agent for patients with pancreatic adenocarcinoma. Proc. Am. Soc. Clin. Oncol 14, 221 (1995).
   Google Scholar
• Casper ES, Green MR, Kasen DR Phase II study of gemcitabine (2'- difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest. New Drugs. 12, 29 (1994).
   Google Scholar
• Burris HA, Moore MJ, Andersen J et al Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. j Clin. 0=1 15, 2403–2413 (1997).
   Google Scholar
• Rothenberg ML, Moore MJ, Cripps MC et al A Phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann. Oncol 7, 347–353 (1996).
   Google Scholar
• Wolffe RA, Chiao P, Lenzi R et al Current approaches and future stratgies for pancreatic carcinoma. Invest. New Drugs. 18, 43–56 (2000).
   PubMedGoogle Scholar
• •An excellent overview of current andfuture treatment options in pancreas cancer.
   Google Scholar
• Thomas AL, Steward WP. Marimastat: the clinical development of a matrix metalloproteinase inhibitor. Expert Opin. Investik Drugs 9, 2912–2922 (2000).
   Google Scholar
• Mulvihill S, Warren R, Fell S. A Phase I trial of intratumoral injection with an E1B-attenuated adenovirus ONYX-015, into unresectable carcinomas of the exocrine pancreas. Proc. Am. Assoc. Clin. Oncol 17, 211a (1998).
   Google Scholar
• Devita Jr VT, Hellman S, Rosenberg SA. Cancer' principles and practice of oncology (5th edition). Lippincott-Raven Publishers, Philadelphia, USA (1997).
   Google Scholar
• Abeloff MD. Oncology and haematology 2000: an intemet resource guide eMedguides.com, Inc., Princeton, New Jersey, USA (2000).
   Google Scholar